本帖最后由 老马 于 2013-3-13 13:43 编辑
. r* k" m6 f" Z3 ^6 ^
$ w4 G9 O0 H, d: J7 |健择（吉西他滨）+顺铂+阿瓦斯汀. C2 d/ \! |/ N3 C' W
Gemzar +Cisplatin + Avastin
' D% X% w, o" ?# R0 Ghttp://annonc.oxfordjournals.org/content/21/9/1804.full/ O8 m" {% q' f! [9 e2 B% |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) # C. D# k& ^" C( a( E& @2 j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" D7 t' O" A2 Z3 z( hResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - J* U9 s2 j! X% B' n
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 973)
2 b$ ~/ A; @4 S5 \% ?& |; ~
华为网盘附件：
9 ^% g# q* t1 E3 x! i3 C【华为网盘】ava.JPG% z: z& @2 G: r6 O! X/ E
|
显身卡
